Eli Lilly to Acquire Monsanto’s Posilac Artificial Growth Hormone Unit
15:17 PM | August 25, 2008 | Kate Phillips
Monsanto says it has agreed to sell its Posilac recombinant bovine somatotropin (rBST) brand and related business to Eli Lilly for an upfront payment of $300 million, plus possible contingency...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.